Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1564)	2/16/2006 1:18:44 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

BSX Started with an upgap after announcing yesterday that its TAXUS Liberté will be available for use on French Hospitals. It traded at 24.60 at 12.46PM & after testing intraday support at 24.44 it is now on its way to retest its intraday H <g> bigcharts.marketwatch.com The stock has closed its Jan.27 downgap and is now trying to close the Jan.17 one <g> bigcharts.marketwatch.com The stock needs to close above 28 in order to get off its longer term downtrend coming from its April 2004 H at 46.10 bigcharts.marketwatch.com The stock traded up 8.8% at its intraday H & is still up more than 8% for the day. Bernard

To: Jibacoa who wrote (1564)	7/16/2007 4:49:39 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

AGEN Is trying to find support at the $2.70 level. bigcharts.marketwatch.com Its 1stQ revenues were up significantly,apparently associated with milestone and manufacturing payments from its QS-21 licensees, & it has continued to trim its losses for 4 consecutive Qs. The stock needs to close above $3.45 in order to start getting off its near term DT & try to test its higher resistance at the May 22 H of $3.74 & the April 16 spike at $5.42 bigcharts.marketwatch.com April 16 was when it presented updated data from a P1/2 on Oncophage in recurrent, high-grade glioma at the meeting of the AANS,showing that Oncophage vaccination was associated with significant tumor-specific immune response in all 12 treated patients from baseline (P <.001) AGEN Needs some more encouraging news before it can test its importance resistance at the $10 level.<g> bigcharts.marketwatch.com Bernard